Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19
IgM and IgG antibodies to the SARS-CoV-2 virus are detected in subjects who have recovered from COVID-19; IgM antibodies persist in a 1/3 of infected subjects up to 12 months from the moment of the disease, while IgG antibodies are present in the vast majority of cases (97%; medium and high levels antibodies were registered in 85% of cases). By the 12th month, 40% of those who recovered still have a very high level of IgG antibodies to the S-protein (>500 BAU/ml). In the feces, urine, and blood serum of patients with long-term persistent IgM antibodies, no coronavirus antigens were detected. After vaccination with the Gam-COVID-Vac vaccine, IgG antibodies to the S-protein are detected in 100% of cases and remain at a high level for 4 months, by the 5-6th month, the level of antibodies decreases. During revaccination, the level of IgG antibodies to S-protein reaches high values earlier than during primary vaccination, and remains high for 4 months (observation period). The blood sera of recovered and vaccinated patients have a high virus-neutralizing activity (at least 1:80), while its level is somewhat higher in recovered patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:173 |
|---|---|
| Enthalten in: |
Bulletin of experimental biology and medicine - 173(2022), 6 vom: Okt., Seite 734-739 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kombarova, S. Yu. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s10517-022-05620-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR048570303 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR048570303 | ||
| 003 | DE-627 | ||
| 005 | 20230519201522.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221109s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10517-022-05620-1 |2 doi | |
| 035 | |a (DE-627)SPR048570303 | ||
| 035 | |a (SPR)s10517-022-05620-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kombarova, S. Yu. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Features of the Humoral Response to Infection, Vaccination, and Revaccination during COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a IgM and IgG antibodies to the SARS-CoV-2 virus are detected in subjects who have recovered from COVID-19; IgM antibodies persist in a 1/3 of infected subjects up to 12 months from the moment of the disease, while IgG antibodies are present in the vast majority of cases (97%; medium and high levels antibodies were registered in 85% of cases). By the 12th month, 40% of those who recovered still have a very high level of IgG antibodies to the S-protein (>500 BAU/ml). In the feces, urine, and blood serum of patients with long-term persistent IgM antibodies, no coronavirus antigens were detected. After vaccination with the Gam-COVID-Vac vaccine, IgG antibodies to the S-protein are detected in 100% of cases and remain at a high level for 4 months, by the 5-6th month, the level of antibodies decreases. During revaccination, the level of IgG antibodies to S-protein reaches high values earlier than during primary vaccination, and remains high for 4 months (observation period). The blood sera of recovered and vaccinated patients have a high virus-neutralizing activity (at least 1:80), while its level is somewhat higher in recovered patients. | ||
| 700 | 1 | |a Aleshkin, A. V. |4 aut | |
| 700 | 1 | |a Novikova, L. I. |4 aut | |
| 700 | 1 | |a Bochkareva, S. S. |4 aut | |
| 700 | 1 | |a Zatevalov, A. M. |4 aut | |
| 700 | 1 | |a Mekhtiev, E. R. |4 aut | |
| 700 | 1 | |a Mizaeva, T. E. |4 aut | |
| 700 | 1 | |a Basov, A. A. |4 aut | |
| 700 | 1 | |a Borisova, O. Yu. |4 aut | |
| 700 | 1 | |a Likhanskaya, E. I. |4 aut | |
| 700 | 1 | |a Voropaeva, E. A. |4 aut | |
| 700 | 1 | |a Urban, Yu. N. |4 aut | |
| 700 | 1 | |a Mitrokhin, S. D. |4 aut | |
| 700 | 1 | |a Shkoda, A. S. |4 aut | |
| 700 | 1 | |a Gushchin, V. A. |4 aut | |
| 700 | 1 | |a Sinyavin, A. E. |4 aut | |
| 700 | 1 | |a Nikiforova, M. A. |4 aut | |
| 700 | 1 | |a Lebedin, Yu. S. |4 aut | |
| 700 | 1 | |a Karaulov, A. V. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin of experimental biology and medicine |d Dordrecht [u.a.] : Springer Science + Business Media B. V., 1956 |g 173(2022), 6 vom: Okt., Seite 734-739 |w (DE-627)SPR010703306 |w (DE-600)2037110-X |x 1573-8221 |7 nnns |
| 773 | 1 | 8 | |g volume:173 |g year:2022 |g number:6 |g month:10 |g pages:734-739 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10517-022-05620-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 173 |j 2022 |e 6 |c 10 |h 734-739 | ||